Scoop: Roche scraps one of two schizophrenia PhII trials after failing the primary endpoint
Roche has terminated one of two Phase II trials testing its drug ralmitaront in patients with schizophrenia, the Big Pharma confirmed to Endpoints News.
The study was terminated last month, according to a June 22 update to the registry on clinicaltrials.gov. Begun in September 2020, the trial was looking at ralmitaront in patients with acute schizophrenia. The trial enrolled 286 patients out of an originally planned 308.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.